Corporate Banner
Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
Become a Member | Sign in
Home>News>This Article

SuppreMol Begins Development of SM401 to Diagnose and Treat RA

Published: Wednesday, July 25, 2012
Last Updated: Tuesday, July 24, 2012
Bookmark and Share
Licensing agreement with the University Hospital of Regensburg.

SuppreMol GmbH has announced a licensing agreement with the University Hospital of Regensburg to develop SM401, a humanized anti-IL-3 monoclonal antibody for early diagnosis and treatment of Rheumatoid Arthritis (RA).

SuppreMol will advance preclinical development of SM401 for treatment of RA.

Simultaneously, the Company will further validate a highly sensitive human IL-3 diagnostic assay for patient stratification.

SuppreMol’s preclinical candidate SM401 has demonstrated, in a murine model for RA, that it significantly reduces progression and severity of the disease.

At the same time, levels of the inflammatory cytokines IL-6 and TNF-alpha, which are reduced by several established RA drugs, are also lowered.

Furthermore, it has been demonstrated that IL-3 concentrations were only elevated at the onset of arthritis and fell to low levels during the course of the disease in the animal model.

Using the newly developed IL-3 diagnostic assay, SuppreMol expects to develop a biomarker for the stratification of RA patients.

“This SM401 program advances SuppreMol's strategy to target very early events in the development of autoimmune diseases,” said Dr. Peter Sondermann, CSO and co-founder of SuppreMol GmbH.

Dr. Sondermann continued, “Through this early intervention approach we expect to stop progression of the autoimmune disease rather than simply treating symptoms of inflammation. We expect to begin clinical trials in 2014.”

The anti-IL-3 monoclonal antibody was generated by the group of Professor Dr. Matthias Mack at Regensburg University Hospital - Internal Medicine II, following the discovery that increased levels of IL-3 indicate early onset and activity of RA. Prof. Mack is a member of SuppreMol’s Scientific Advisory Board.

“This licensing agreement with Bayerische Patentallianz GmbH provides SuppreMol a very strong portfolio of autoimmune therapies and a potential companion RA diagnostic,” said Professor Dr. Peter Buckel, CEO of SuppreMol GmbH.

“Along with our Fc gamma receptor platform with three clinical and two further preclinical programs targeting autoimmune diseases and allergies, this SM401 program is another building block in the strong foundation of the company’s future,” he added.

Bayerische Patentallianz GmbH is the central patent and marketing agency of the Bavarian Universities and Universities of Applied Sciences, including the University of Regensburg.

Early development of SM401 is being funded by a grant of € 1.37 million from the German Federal Ministry of Education and Research (BMBF).

The project was funded in Prof. Mack’s laboratory through BayImmuNet, the Bayerisches Immuntherapie Netzwerk; the development of a therapeutic anti-IL-3 antibody including a highly sensitive IL-3 assay is supported by the German Federal Ministry of Education and Research within the Leading-Egde Cluster “m4 - Personalized Medicine and Targeted Therapies” in Munich.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Scientific News
Measuring microRNAs in Blood to Speed Cancer Detection
A simple, ultrasensitive microRNA sensor holds promise for the design of new diagnostic strategies and, potentially, for the prognosis and treatment of pancreatic and other cancers.
Biomedical Imaging at One-Thousandth the Cost
Mathematical modeling enables $100 depth sensor to approximate the measurements of a $100,000 piece of lab equipment.
Improving Outcomes for Lung Cancer and Diabetic Patients
Novel technologies have been developed with support from SBRI Healthcare funding.
New Way of Detecting Cancer
A new RNA test of blood platelets can be used to detect, classify and pinpoint the location of cancer by analysing a sample equivalent to one drop of blood.
Rapid, Portable Ebola Diagnostic
Scientists confirmed the efficiency of the novel Ebola detection method in field trials.
New, Better Test for Prostate Cancer
A study from Karolinska Institutet shows that a new test for prostate cancer is better at detecting aggressive cancer than PSA.
Blood Test Picks Out Prostate Cancer Drug Resistance
Scientists have developed a blood test that can identify key mutations driving resistance to a widely used prostate cancer drug, and identify in advance patients who will not respond to treatment.
Antibody Targets Key Cancer Marker
University of Wisconsin-Madison researchers have created a molecular structure that attaches to a molecule on highly aggressive brain cancer and causes tumors to light up in a scanning machine.
Key Piece of MRSA Vaccine Puzzle
New research funded by the Health Research Board and the Wellcome Trust has pinpointed immune cells that could be targeted by an MRSA vaccine.
Biomarker Finder Adjusts On the Fly
Rice University scientists build better tool to find signs of disease.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos